# A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

> **NCT00369889** · PHASE2 · COMPLETED · sponsor: **Indiana University** · enrollment: 18 (actual)

## Conditions studied

- Thymic Cancer
- Thymoma

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00369889
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369889, "A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00369889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*